Search results for "Estrogen."

showing 10 items of 529 documents

C-myc mRNA Expression in Epithelial Ovarian Carcinomas in Relation to Estrogen Receptor Status, Metastatic Spread, Survival Time, FIGO Stage, and His…

1998

Recently, it has been suggested that c-myc expression might correlate with estrogen receptor (ER) status and metastatic spread in ovarian cancer. In this study, expression of c-myc mRNA in 90 epithelial ovarian carcinomas was determined using the S1 nuclease protection assay. Expression of c-myc mRNA was detectable in 27 of 90 tumors. There was no significant association between c-myc mRNA expression and metastatic spread, survival time, FIGO stage, or histologic grade and type. C-myc mRNA was expressed in 45% of ER-positive tumors but only 24% of ER-negative tumors (p = 0.094; Fisher's exact test). Similarly, 44% of progesterone receptor (PR)-positive and 23% of PR-negative tumors expresse…

Pathologymedicine.medical_specialtymedicine.drug_class10050 Institute of Pharmacology and ToxicologyEstrogen receptor610 Medicine & healthOvaryBiologyPathology and Forensic MedicineMetastasisProto-Oncogene Proteins c-mycProgesterone receptormedicineHumansRNA MessengerRNA NeoplasmSurvival rateEstrogen Receptor StatusOvarian NeoplasmsCarcinomaObstetrics and Gynecology2729 Obstetrics and Gynecologymedicine.diseaseSurvival Rate2734 Pathology and Forensic Medicinemedicine.anatomical_structureReceptors EstrogenEstrogen570 Life sciences; biologyFemaleReceptors ProgesteroneOvarian cancerInternational Journal of Gynecological Pathology
researchProduct

Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in hum…

1986

The present study performed on a total of 567 cases of human female breast cancer compares the results of the biochemical assay (dextran-coated charcoal assay = DCC) for oestrogen receptor (ER) with those of several morphological methods developed for the detection of the ER or for the prediction of prognosis by use of other systems (FSA = fluorescent ligand binding assay, ER-ICA = monoclonal antibody assay for ER, LRA = lectin receptor assay using peanut agglutinin, and Barr body estimation). Whereas no correlation at all was observed among the results of the DCC and those of the FSA and Barr body estimation, the ER-ICA and the LRA showed an unanimous tendency towards higher values of ER w…

Peanut agglutininPathologymedicine.medical_specialtymedicine.drug_classBreast NeoplasmsMonoclonal antibodyPathology and Forensic MedicinePeanut AgglutininLectinsmedicineHumansLymphocytesReceptorMolecular BiologyFluorescent DyesImmunoassaybiologyHistocytochemistryLigand binding assayAssayCancerAntibodies MonoclonalDextransCell BiologyGeneral Medicinemedicine.diseaseFluoresceinsMolecular biologyReceptors EstrogenSex ChromatinCharcoalReceptors MitogenMonoclonalbiology.proteinImmunohistochemistryFemaleFluorescein-5-isothiocyanateThiocyanatesVirchows Archiv. A, Pathological anatomy and histopathology
researchProduct

Effect of hormone replacement therapy (HRT) on periodontal status of postmenopausal women.

2011

Summary Background The risks/benefits balance of hormone replacement therapy (HRT) is controversial. The aim of this study was to assess the periodontal status of a postmenopausal women group receiving HRT and to determine the effects of HRT on clinical measures of periodontal disease. Material/Methods Ninety-one postmenopausal women, 52 taking HRT (HRT+) and 39 not taking HRT (HRT−), completed the study. Clinical parameters measured included visible supragingival plaque, probing pocket depth (PD) and clinical attachment level (CAL). Gingival status was recorded as gingival bleeding on probing (BOP). Previous oral contraceptive use and current and past smoking status were also assessed. Res…

Periodontiummedicine.medical_specialtygenetic structuresPeriodontal diseaseSettore MED/28 - Malattie OdontostomatologicheInternal medicineMedicineHumansEstrogen replacement therapyperiodontitisGynecologyPostmenopausal womenbusiness.industryEstrogen Replacement TherapyGeneral MedicineMiddle Agedeye diseaseshormone replacement therapypostmenopausefemaleTransgender hormone therapyhormone replacement therapy (HRT) postmenopause chronic periodontitis gingivitis femalesense organsPublic HealthbusinessgingivitisMedical science monitor : international medical journal of experimental and clinical research
researchProduct

Argan oil prevents down-regulation induced by endotoxin on liver fatty acid oxidation and gluconeogenesis and on peroxisome proliferator-activated re…

2015

In patients with sepsis, liver metabolism and its capacity to provide other organs with energetic substrates are impaired. This and many other pathophysiological changes seen in human patients are reproduced in mice injected with purified endotoxin (lipopolysaccharide, LPS). In the present study, down-regulation of genes involved in hepatic fatty acid oxidation (FAOx) and gluconeogenesis in mice exposed to LPS was challenged by nutritional intervention with Argan oil. Mice given a standard chow supplemented or not with either 6% (w/w) Argan oil (AO) or 6% (w/w) olive oil (OO) prior to exposure to LPS were explored for liver gene expressions assessed by mRNA transcript levels and/or enzyme a…

Peroxisome proliferator-activated receptor gammamedicine.medical_specialtyOO olive oilResearch paper[SDV]Life Sciences [q-bio]Peroxisome proliferator-activated receptorBiologyBiochemistryNuclear receptor 30lcsh:BiochemistryEstrogen-related receptorEstrogen-related receptor alphaInternal medicineACADS acyl CoA dehydrogenase short-chainACADL acyl CoA dehydrogenase long-chainmedicinePGC-1α peroxisome proliferator-activated receptor γ coactivator-1αlcsh:QD415-436ReceptorBeta oxidationHNF-4α hepatic nuclear factor-4αchemistry.chemical_classificationACADM acyl CoA dehydrogenase medium-chainPPARα peroxisome proliferator-activated receptor αERRα estrogen related receptor α[ SDV ] Life Sciences [q-bio]PEPCK phospoenolpyruvate carboxykinaseGluconeogenesisBeta-oxidationGlut4 glucose transporter 4[SDV] Life Sciences [q-bio]G6PH glucose-6-phosphataseEndocrinologyGlut2 glucose transporter 2chemistryNuclear receptorArgan oilAO Argan oilNuclear receptorACOX1 acyl-CoA oxidase 1CoactivatorLPS lipopolysaccharidePeroxisome proliferator-activated receptor alpha
researchProduct

Gas chromatography/mass spectrometry of catechol estrogens

1992

Abstract Catecholestrogens (CCEs), namely 2- or 4-hydroxyestradiol and hydroxyestrone, are highly polar, reactive, and extremely labile estrogen metabolites in many experimental conditions. For these reasons, indirect assay methods mainly have been used. Some experimental evidence suggests that CCEs are synthesized and biologically active mostly in target cells. At this level, unfortunately, the indirect assays cannot be used. We present a method of gas Chromatographic/mass spectral (GC/MS) analysis for the identification of individual CCEs; the major fragmentation ions of authentic estrogen standards as trimethylsilylether derivatives, and the MS patterns of the major CCEs, namely, 2-hydro…

PharmacologyDetection limitCatecholChromatographyElutionOrganic ChemistryClinical BiochemistryPolyatomic ionBreast NeoplasmsBiological activityMass spectrometryBiochemistryEstrogens CatecholGas Chromatography-Mass Spectrometrychemistry.chemical_compoundEndocrinologychemistryHumansFemaleGas chromatographyGas chromatography–mass spectrometryFibrocystic Breast DiseaseMolecular BiologyChromatography High Pressure LiquidSteroids
researchProduct

Single-digit nanomolar inhibitors lock the aromatase active site via a dualsteric targeting strategy

2022

The most frequently diagnosed breast cancer (BC) type in women expresses estrogen receptor (ER) , depends on estrogens for its growth, being classified as ER positive (ER+). The gold standard therapy for the treatment of this tumor relies on the inhibition of the aromatase enzyme, which catalyzes estrogen biosynthesis. Despite the clinical success of current aromatase inhibitors (AIs), after prolonged therapeutic regimens, BC ER + patients experience acquired resistance and disease relapse. This points up the urgent need for a newer generation of AIs able to overcome resistance issues, while mitigating toxicity and side effects of current therapies. Here we performed the synthesis, biologic…

PharmacologyOrganic ChemistryBreast NeoplasmsGeneral MedicineMolecular dynamicsQM/MMAromataseAllosteric inhibitionAromatase inhibitorsBreast cancerReceptors EstrogenSettore CHIM/03 - Chimica Generale E InorganicaCatalytic DomainDrug DiscoveryBreast cancer; Aromatase inhibitors; Allosteric inhibition; Molecular dynamics; QM; MMHumansFemaleEuropean Journal of Medicinal Chemistry
researchProduct

Ah receptor mediating induction of cytochrome P450IA1 in a novel continuous human liver cell line (Mz-Hep-1)

1991

Abstract The Ah receptor regulates induction of cytochrome P450IA1 and mediates certain toxicities of polyhalogenated aromatics such as 2,3,7,8-tetrachlorodibenzo- p -dioxin (TCDD). It has been characterized previously in continuous cell lines, notably the mouse hepatoma line Hepa 1, the human squamous cell carcinoma line A431, and the human liver cell line Hep G2. The present work extends our knowledge of the Ah receptor in continuous human liver cell lines. Ah receptor can be detected in Mz-Hep-1, a hepatitis B virus-negative cell line derived from a Thorotrast-induced hepatocellular carcinoma. The mean concentration of Ah receptor in Mz-Hep-1 cells was 341 ± 22 fmol/mg cytosol protein (m…

PharmacologyReceptor complexChemistryEstrogen receptorBiochemistryHep G2Dissociation constantGlucocorticoid receptorMechanism of actionBiochemistryCell culturemedicinemedicine.symptomGlucocorticoidmedicine.drugBiochemical Pharmacology
researchProduct

MicroRNA-30d deficiency during preconception affects endometrial receptivity by decreasing implantation rates and impairing fetal growth.

2019

Background Maternal–embryonic crosstalk between the endometrium and the preimplantation embryo is required for normal pregnancy. Our previous results demonstrated that maternal microRNAs secreted into the endometrial fluid, specifically miR-30d, act as a transcriptomic regulator of the preimplantation embryo by the maternal intrauterine environment. Objective To investigate the reproductive and fetal effects of murine miR-30d deficiency at the maternal–embryonic interface according to the origin of its maternal or embryonic default. Study Design A miR-30d knockout murine model was used as the animal model to investigate the impact of maternal and/or embryonic origin of miR-30d deficiency on…

PlacentaEndometriumReal-Time Polymerase Chain ReactionLeukemia Inhibitory FactorAndrologyFetal Development03 medical and health sciencesEndometriumMice0302 clinical medicinePregnancymedicineAnimals030212 general & internal medicineEmbryo ImplantationHomeodomain ProteinsMSX1 Transcription FactorMice KnockoutFetusPregnancy030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyGene Expression Regulation DevelopmentalEmbryomedicine.diseaseEmbryo TransferEmbryonic stem cellPlacentationMicroRNAsmedicine.anatomical_structureReal-time polymerase chain reactionReceptors EstrogenCyclooxygenase 2GestationSmall for gestational ageFemalebusinessReceptors ProgesteroneAmerican journal of obstetrics and gynecology
researchProduct

Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase.

2002

Background— Estrogens can upregulate endothelial nitric oxide synthase (eNOS) in human endothelial cells by increasing eNOS promoter activity and enhancing the binding activity of the transcription factor Sp1. Resveratrol, a polyphenolic phytoalexin found in grapes and wine, has been reported to act as an agonist at the estrogen receptor. Therefore, we tested the effect of this putative phytoestrogen on eNOS expression in human endothelial cells. Methods and Results— Incubation of human umbilical vein endothelial cells (HUVEC) and HUVEC-derived EA.hy 926 cells with resveratrol for 24 to 72 hours upregulated eNOS mRNA expression in a time- and concentration-dependent manner (up to 2.8-fold)…

PolymersRNA StabilityElectrophoretic Mobility Shift AssayWineResveratrolUmbilical veinchemistry.chemical_compoundEnosStilbenesPromoter Regions GeneticCells Culturedchemistry.chemical_classificationbiologyPhytoalexinEstrogen Antagonistsfood and beveragesNitric Oxide Synthase Type IIIUp-RegulationNitric oxide synthasemedicine.anatomical_structureReceptors EstrogenEnzyme InductionCardiology and Cardiovascular MedicineSesquiterpenesmedicine.medical_specialtyEndotheliumNitric Oxide Synthase Type IIINuclease Protection AssaysEnzyme ActivatorsPhytoestrogensNitric OxidePhenolsPhytoalexinsPhysiology (medical)Internal medicinemedicineHumansEstrogens Non-SteroidalRNA MessengerFlavonoidsSp1 transcription factorPlant ExtractsTerpenesPolyphenolsbiology.organism_classificationMolecular biologyIsoflavonesEnzyme ActivationEndocrinologychemistryResveratrolbiology.proteinEndothelium VascularPlant PreparationsNitric Oxide SynthaseCirculation
researchProduct

Effect of estrogen in malignant melanoma

2021

Background Melanoma is associated with poor prognosis in its advanced stages. Potential influence of estrogen and its metabolites on melanoma growth has been suggested. Aims The objective of this review was to provide an overview on the evidence related to estrogen in malignant melanoma. Materials and methods Literature search using PubMed, Google Scholar and relevant cross-references of the retrieved articles was performed to review relevant published articles related to estrogen and its effects in malignant melanoma. Results Effect of estrogen signaling on a tissue largely depends on the relative expression of estrogen receptors (ER) α and β. Gender differences in melanoma may be explaine…

Poor prognosisSkin Neoplasmsbusiness.industrymedicine.drug_classMelanomaEstrogen Receptor alpha610 MedizinEstrogen receptorStimulationEstrogensDermatologymedicine.diseaseMetastasisEstrogen610 Medical sciencesCancer researchEstrogen signalingMedicineEstrogen Receptor betaHumansbusinessReceptorMelanoma
researchProduct